Literature DB >> 28663208

Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Potential for a Universal Influenza Vaccine.

James E Crowe1.   

Abstract

Development of optimal vaccines for influenza is challenging, in part as a result of the high antigenic variability in field strains associated with genetic shift from reassortment and genetic drift from point mutations. Discovery of conserved antigenic sites on the hemagglutinin (HA) protein for neutralizing antibodies suggested the possibility that influenza vaccines could be developed that induce focused antibody responses to the conserved neutralizing determinants, especially the HA stem region. Recent studies have focused on the antigenicity and immunogenicity of such domains, using monoclonal antibodies and candidate-engineered HA stem-based vaccines. Much progress has been made, but we still do not fully understand the biology of the immune response to this unique antigenic region.
Copyright © 2018 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28663208      PMCID: PMC5829045          DOI: 10.1101/cshperspect.a029496

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Biol        ISSN: 1943-0264            Impact factor:   10.005


  37 in total

1.  Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy-chain lineages.

Authors:  James R R Whittle; Adam K Wheatley; Lan Wu; Daniel Lingwood; Masaru Kanekiyo; Steven S Ma; Sandeep R Narpala; Hadi M Yassine; Gregory M Frank; Jonathan W Yewdell; Julie E Ledgerwood; Chih-Jen Wei; Adrian B McDermott; Barney S Graham; Richard A Koup; Gary J Nabel
Journal:  J Virol       Date:  2014-02-05       Impact factor: 5.103

2.  Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo.

Authors:  David J DiLillo; Gene S Tan; Peter Palese; Jeffrey V Ravetch
Journal:  Nat Med       Date:  2014-01-12       Impact factor: 53.440

3.  A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins.

Authors:  Davide Corti; Jarrod Voss; Steven J Gamblin; Giosiana Codoni; Annalisa Macagno; David Jarrossay; Sebastien G Vachieri; Debora Pinna; Andrea Minola; Fabrizia Vanzetta; Chiara Silacci; Blanca M Fernandez-Rodriguez; Gloria Agatic; Siro Bianchi; Isabella Giacchetto-Sasselli; Lesley Calder; Federica Sallusto; Patrick Collins; Lesley F Haire; Nigel Temperton; Johannes P M Langedijk; John J Skehel; Antonio Lanzavecchia
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

4.  Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada.

Authors:  Danuta M Skowronski; Gaston De Serres; Natasha S Crowcroft; Naveed Z Janjua; Nicole Boulianne; Travis S Hottes; Laura C Rosella; James A Dickinson; Rodica Gilca; Pam Sethi; Najwa Ouhoummane; Donald J Willison; Isabelle Rouleau; Martin Petric; Kevin Fonseca; Steven J Drews; Anuradha Rebbapragada; Hugues Charest; Marie-Eve Hamelin; Guy Boivin; Jennifer L Gardy; Yan Li; Trijntje L Kwindt; David M Patrick; Robert C Brunham
Journal:  PLoS Med       Date:  2010-04-06       Impact factor: 11.069

5.  Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies.

Authors:  Sinthujan Jegaskanda; Emma R Job; Marit Kramski; Karen Laurie; Gamze Isitman; Robert de Rose; Wendy R Winnall; Ivan Stratov; Andrew G Brooks; Patrick C Reading; Stephen J Kent
Journal:  J Immunol       Date:  2013-01-14       Impact factor: 5.422

6.  Structure and accessibility of HA trimers on intact 2009 H1N1 pandemic influenza virus to stem region-specific neutralizing antibodies.

Authors:  Audray K Harris; Joel R Meyerson; Yumiko Matsuoka; Oleg Kuybeda; Amy Moran; Donald Bliss; Suman R Das; Jonathan W Yewdell; Guillermo Sapiro; Kanta Subbarao; Sriram Subramaniam
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-04       Impact factor: 11.205

7.  Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes.

Authors:  Ana Clara Monsalvo; Juan P Batalle; M Florencia Lopez; Jens C Krause; Jennifer Klemenc; Johanna Zea Hernandez; Bernardo Maskin; Jimena Bugna; Carlos Rubinstein; Leandro Aguilar; Liliana Dalurzo; Romina Libster; Vilma Savy; Elsa Baumeister; Liliana Aguilar; Graciela Cabral; Julia Font; Liliana Solari; Kevin P Weller; Joyce Johnson; Marcela Echavarria; Kathryn M Edwards; James D Chappell; James E Crowe; John V Williams; Guillermina A Melendi; Fernando P Polack
Journal:  Nat Med       Date:  2010-12-05       Impact factor: 53.440

8.  Seasonal influenza vaccine and increased risk of pandemic A/H1N1‐related illness: first detection of the association in British Columbia, Canada.

Authors:  Naveed Z Janjua; Danuta M Skowronski; Travis S Hottes; William Osei; Evan Adams; Martin Petric; Suzana Sabaiduc; Tracy Chan; Annie Mak; Marcus Lem; Patrick Tang; David M Patrick; Gaston De Serres; David Bowering
Journal:  Clin Infect Dis       Date:  2010-11-01       Impact factor: 9.079

9.  IGHV1-69 polymorphism modulates anti-influenza antibody repertoires, correlates with IGHV utilization shifts and varies by ethnicity.

Authors:  Yuval Avnir; Corey T Watson; Jacob Glanville; Eric C Peterson; Aimee S Tallarico; Andrew S Bennett; Kun Qin; Ying Fu; Chiung-Yu Huang; John H Beigel; Felix Breden; Quan Zhu; Wayne A Marasco
Journal:  Sci Rep       Date:  2016-02-16       Impact factor: 4.379

10.  Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes.

Authors:  Nicole L Kallewaard; Davide Corti; Patrick J Collins; Ursula Neu; Josephine M McAuliffe; Ebony Benjamin; Leslie Wachter-Rosati; Frances J Palmer-Hill; Andy Q Yuan; Philip A Walker; Matthias K Vorlaender; Siro Bianchi; Barbara Guarino; Anna De Marco; Fabrizia Vanzetta; Gloria Agatic; Mathilde Foglierini; Debora Pinna; Blanca Fernandez-Rodriguez; Alexander Fruehwirth; Chiara Silacci; Roksana W Ogrodowicz; Stephen R Martin; Federica Sallusto; JoAnn A Suzich; Antonio Lanzavecchia; Qing Zhu; Steven J Gamblin; John J Skehel
Journal:  Cell       Date:  2016-07-21       Impact factor: 41.582

View more
  9 in total

1.  A Lipid/DNA Adjuvant-Inactivated Influenza Virus Vaccine Protects Rhesus Macaques From Uncontrolled Virus Replication After Heterosubtypic Influenza A Virus Challenge.

Authors:  Timothy D Carroll; Sinthujan Jegaskanda; Shannon R Matzinger; Linda Fritts; Michael B McChesney; Stephen J Kent; Jeffery Fairman; Christopher J Miller
Journal:  J Infect Dis       Date:  2018-08-14       Impact factor: 5.226

2.  The post-2009 influenza pandemic era: time to revisit antibody immunodominance.

Authors:  Kristien Van Reeth
Journal:  J Clin Invest       Date:  2018-10-08       Impact factor: 14.808

3.  Hemagglutinin head-specific responses dominate over stem-specific responses following prime boost with mismatched vaccines.

Authors:  Sinthujan Jegaskanda; Sarah F Andrews; Adam K Wheatley; Jonathan W Yewdell; Adrian B McDermott; Kanta Subbarao
Journal:  JCI Insight       Date:  2019-11-14

4.  Magnitude and breadth of antibody cross-reactivity induced by recombinant influenza hemagglutinin trimer vaccine is enhanced by combination adjuvants.

Authors:  Jenny E Hernandez-Davies; Emmanuel P Dollinger; Egest J Pone; Jiin Felgner; Li Liang; Shirin Strohmeier; Sharon Jan; Tyler J Albin; Aarti Jain; Rie Nakajima; Algimantas Jasinskas; Florian Krammer; Aaron Esser-Kahn; Philip L Felgner; Qing Nie; D Huw Davies
Journal:  Sci Rep       Date:  2022-06-02       Impact factor: 4.996

5.  Hide and seek: interplay between influenza viruses and B cells.

Authors:  Masayuki Kuraoka; Yu Adachi; Yoshimasa Takahashi
Journal:  Int Immunol       Date:  2020-09-08       Impact factor: 4.823

6.  Development of a high-throughput assay to detect antibody inhibition of low pH induced conformational changes of influenza virus hemagglutinin.

Authors:  Jessica F Trost; Elizabeth H LeMasters; Feng Liu; Paul Carney; Xiuhua Lu; Kanetsu Sugawara; Seiji Hongo; James Stevens; David A Steinhauer; Terrence Tumpey; Jacqueline M Katz; Min Z Levine; Zhu-Nan Li
Journal:  PLoS One       Date:  2018-06-27       Impact factor: 3.240

Review 7.  A year of terror and a century of reflection: perspectives on the great influenza pandemic of 1918-1919.

Authors:  Michaela E Nickol; Jason Kindrachuk
Journal:  BMC Infect Dis       Date:  2019-02-06       Impact factor: 3.090

Review 8.  The Quest for a Truly Universal Influenza Vaccine.

Authors:  Yo Han Jang; Baik Lin Seong
Journal:  Front Cell Infect Microbiol       Date:  2019-10-10       Impact factor: 5.293

9.  A Novel Immunobiotics Bacteroides dorei Ameliorates Influenza Virus Infection in Mice.

Authors:  Liqiong Song; Yuanming Huang; Guoxing Liu; Xianping Li; Yuchun Xiao; Chang Liu; Yue Zhang; Jintong Li; Jianguo Xu; Shan Lu; Zhihong Ren
Journal:  Front Immunol       Date:  2022-01-26       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.